"What" Series

What is a placebo in clinical trials?

17 January 2024
2 min read

In clinical trials, a placebo is an inactive substance or other intervention that looks the same and tastes the same as the active drug being tested. The person giving the placebo believes it to be the real drug, but its not. The person taking the placebo doesnt know if they are getting the real drug or the placebo.
The use of placebos in clinical trials is controversial because some people argue that its unethical to give a patient a sugar pill when there might be an effective treatment available. However, others argue that its important to have a control group in clinical trials so that researchers can compare the results of the experimental treatment to a baseline that shows what would happen naturally without the treatment.

In medical procedure or device related clinical trials, sham treatments means the doctor goes through the motions without actually performing the treatment.

In fact, placebo and sham are different concept in the clinical trials.

EyePoint Pharma announces first patient treatment in early-phase VERONA trial for EYP-1901 in diabetic eye swelling
Latest Hotspot
3 min read
EyePoint Pharma announces first patient treatment in early-phase VERONA trial for EYP-1901 in diabetic eye swelling
17 January 2024
EyePoint Pharma reports initial participant receives treatment in early-stage VERONA study assessing EYP-1901 for diabetic eye swelling.
Read →
What is a sham in clinical trials?
"What" Series
2 min read
What is a sham in clinical trials?
17 January 2024
In clinical trials, a sham is a procedure or device that looks the same and feels the same as an active treatment being tested but doesn’t actually do anything.
Read →
Ariceum Therapeutics has applied for a UK Clinical Trial Authorization to start testing its new Iodine-123 labeled PARP inhibitor in recurrent glioblastoma patients
Latest Hotspot
3 min read
Ariceum Therapeutics has applied for a UK Clinical Trial Authorization to start testing its new Iodine-123 labeled PARP inhibitor in recurrent glioblastoma patients
17 January 2024
Ariceum Therapeutics has submitted an application for a Clinical Trial Authorization (CTA) in the UK to conduct initial trials of its novel Iodine-123 tagged PARP inhibitor, targeting recurrent glioblastoma patients.
Read →
What's clinical adverse event and it's classification?
"What" Series
2 min read
What's clinical adverse event and it's classification?
17 January 2024
Clinical adverse events (AEs) are any unintended or harmful signs, symptoms, or conditions linked in time to the use of a medical product, regardless of causality.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.